

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Cuttitta et al.

Application No. 09/931,700

Filed: August 16, 2001

Confirmation No. 3744

For: FUNCTIONAL ROLE OF  
ADRENOMEDULLIN (AM) AND THE  
GENE RELATED PRODUCT (PAMP) IN  
HUMAN PATHOLOGY AND  
PHYSIOLOGY

Examiner: Susan Ungar, Ph.D.

Art Unit: 1642

Attorney Reference No. 4239-63842-01

MAIL STOP AMENDMENT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent  
for Applicant(s)

Date Mailed October 12, 2004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.


Submitted herewith is a check for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of the transmittal sheet for this IDS is enclosed.


The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By   
Gillian L. Bunker, Ph.D.  
Registration No. 47,461

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446



**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Attorney Docket Number	4239-63842-01
Application Number	09/931,700
Filing Date	August 16, 2001
First Named Inventor	Cuttitta
Art Unit	1642
Examiner Name	Susan Ungar, Ph.D.

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Cuttitta <i>et al.</i> , "Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer," <i>Nature</i> 316(6031):823-826, 1985
		Ishikawa <i>et al.</i> , "Adrenomedullin Antagonist Suppresses <i>in Vivo</i> Growth of Human Pancreatic Cancer Cells in SCID Mice by Suppressing Angiogenesis," <i>Oncogene</i> 22:1238-1242, 2003.
		Martínez <i>et al.</i> , "Is Adrenomedullin a Causal Agent in Some Cases of Type 2 Diabetes?" <i>Peptides</i> 20:1471-1478, 1999.
		Martínez <i>et al.</i> , "Regulation of Insulin Secretion and Blood Glucose Metabolism by Adrenomedullin," <i>Endocrinology</i> 137(6):2626-2632, 1996.
		Ouafik <i>et al.</i> , "Neutralization of Adrenomedullin Inhibits the Growth of Human Glioblastoma Cell Lines <i>in Vitro</i> and Suppresses Tumor Xenograft Growth <i>in Vivo</i> ," <i>American Journal of Pathology</i> 160(4):1279-1292, 2002.
		Ruggeri <i>et al.</i> , "CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models," <i>Cancer Research</i> 63:5978-5991, 2003.

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.